WRENFIELD · Biotech Intelligence
SYSoperational INGESTCT.GOV · PUBMED · COMPANIES HOUSE · ABR · SEC EDGAR · USPTO UTC00:00:00 UTC BUILDv0.1.0-alpha
BIOTECH INTELLIGENCE INFRASTRUCTURE · EST. MMXXVI

Public data, systematically compiled.

Clinical trials, peer-reviewed publications, patent filings, and corporate registries — aggregated into a single queryable surface. Free for researchers. Built for operators.

Trials Indexed
440,091
+127 past 24h
Publications
35,247,103
+4,812 past 24h
Companies Tracked
12,891
47 jurisdictions
Patent Records
2,184,552
USPTO · EPO · WIPO

Live Signals

LAST 24H · AUTO-INGESTED · NO EDITORIAL OVERLAY
03:41 UTC
TRIAL · PHASE ADV
PHASE 3 Revolution Medicines advanced RMC-6236 (RAS(ON) multi-selective inhibitor) into pivotal study for pancreatic adenocarcinoma.
REVMED · NCT065…
02:18 UTC
PATENT · GRANT
CSL Behring LLC granted US 12,145,983 — compositions and methods relating to factor IX variants. 14 claims, first independent covers recombinant half-life extension.
CSL · USPTO
01:52 UTC
REGISTRY · DIR CHANGE
Telix Pharmaceuticals Ltd [ACN 616 620 369] — appointment of new director effective prior business day. Concurrent ASX price notation within 2.7% of 90d trailing average. ACTIVE
TLX · ASIC
23:04 UTC
TRIAL · HALT
PHASE 2 HALTED Arcturus Therapeutics — sponsor-initiated pause in NCT05··· pending protocol amendment. Secondary endpoint reporting deferred.
ARCT · CT.GOV
22:33 UTC
PUBLICATION
Nature Medicine — first-in-human results published, Mersana Therapeutics B7-H4 ADC. Signal concentration: oncology business development teams, US·CH·DE.
MRSN · PMID 40···
21:07 UTC
REGISTRY · NEW
New entity incorporated: Parkville Bio Pty Ltd [ACN 689 ··· ···]. Directors previously held positions at two Victorian biotech entities (2018–2024). Jurisdiction: VIC.
ASIC
19:42 UTC
FILING · 8-K
Mirati Therapeutics 8-K filed covering subsidiary integration post-acquisition. KRAS pipeline consolidation under BMS Oncology. COMPLETED
BMY · SEC
17:18 UTC
TRIAL · RESULT
PHASE 3 Topline readout posted to ClinicalTrials.gov — primary endpoint met, OS HR 0.72 [0.61–0.86]. Company profile updated automatically.
CT.GOV

Signals shown are representative of platform output. Live ingestion activates on v0.2 launch.

POSITIONING

Bloomberg for biotech.

The global biotech ecosystem generates vast public data — 440,000 registered trials, 35 million publications, millions of patents, every public filing of every listed company — that is systematically underexploited because no single surface has compiled it for the researchers, analysts, and operators who need it.

Existing paid tools charge US$15,000–50,000 per seat. The PhD student, the seed-stage biotech, the journalist covering a trial readout — none of them have access. The free layer of biotech intelligence essentially does not exist. Wrenfield is that layer.

Methodology About the firm